ROBIN SIEFKER: Open Payments
NPI 1730379272 · MARION, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,414 in 169 payments from 19 companies in 2025. Trend: 2023 $2,179 · 2024 $2,568 · 2025 $3,414
Food & beverage: $3,414
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $463 |
| Vanda Pharmaceuticals Inc. | 17 | $407 |
| Janssen Pharmaceuticals, Inc | 18 | $357 |
| ABBVIE INC. | 24 | $340 |
| Alkermes, Inc. | 22 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $291 |
| Otsuka America Pharmaceutical, Inc. | 7 | $228 |
| Axsome Therapeutics, Inc. | 6 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $157 |
| Supernus Pharmaceuticals, Inc. | 8 | $134 |
Products named: INGREZZA, FANAPT, VRAYLAR, CAPLYTA, ARISTADA, INVEGA SUSTENNA, Auvelity, REXULTI.
Industry payments across OH — which companies pay providers there.
